Breaking News Instant updates and real-time market news.

LJPC

La Jolla

$32.36

0.88 (2.80%)

09:04
08/08/17
08/08
09:04
08/08/17
09:04

La Jolla announces launch of expanded access program for LJPC-501

La Jolla Pharmaceutical announced that the company has initiated an expanded access program in the U.S. to provide its investigational drug, LJPC-501, to patients with vasodilatory or distributive shock who cannot achieve target mean arterial pressure despite adequate fluid resuscitation and treatment with currently available vasopressors. The LJPC-501 EAP is a program for U.S. patients 18 years of age or older with vasodilatory or distributive shock who are unable to achieve target MAP despite adequate fluid resuscitation and treatment with currently available vasopressors. The enrollment criteria are available at www.clinicaltrials.gov.

LJPC La Jolla
$32.36

0.88 (2.80%)

04/20/17
RHCO
04/20/17
NO CHANGE
RHCO
La Jolla LJPC-501 likely to be approved, says SunTrust
After speaking with La Jolla's management, SunTrust analyst Yatin Suneja continues to expect the company's LJPC-501 drug "to be approved and become the standard of care in last-line catecholamine-resistant hypotension." The analyst says that the company continues to expect to file for approval of the drug in 2H17. Suneja reports that the company expects to use one primary endpoint - "percentage of patients achieving a mean arterial pressure greater than or equal to75mmHg or a 10mmHg increase from baseline MAP at 3 hours - suggested by the FDA for its Phase 3 trial. Suneja updated the estimates on the company to reflect its follow-on offering and opex adjustments. He keeps a $57 price target and a Buy rating on the shares.
05/18/17
RHCO
05/18/17
NO CHANGE
Target $57
RHCO
Buy
SunTrust 'pleasantly surprised' by today's news from La Jolla
SunTrust analyst Yatin Suneja is "pleasantly surprised" by La Jolla Pharmaceutical's announcement today that the New England Journal of Medicine will publish LJPC-501's Phase III study in catecholamine-resistant hypotension. The "highly prestigious" journal publication highlights both the high unmet need in the CRH population and the benefit LJPC-501 could provide, Suneja tells investors in a research note. He has a Buy rating on the shares with a $57 price target. La Jolla in afternoon trading is up 15%, or $4.32, to $32.34.
05/22/17
JEFF
05/22/17
NO CHANGE
Target $40
JEFF
Buy
La Jolla Phase 3 data in-line with prior top-line data, says Jefferies
Jefferies analyst Eun Yang views last week's 20% rise in La Jolla Pharmaceutical shares as "surprising" since key findings from the detailed Phase 3 data are in-line with prior top-line data. The analyst continues to view FDA approvability for LJPC-501 as high, but feels the commercial potential "could be debatable." Despite the reduction in catecholamine use with LJPC-501, there does not appear difference in cardiac disorders/safety between the LJPC-50 and placebo groups, Yang tells investors in a research note. The analyst keeps a Buy rating on La Jolla with a $40 price target.
05/22/17
RHCO
05/22/17
NO CHANGE
RHCO
La Jolla data positive, says SunTrust
SunTrust analyst Yatin Suneja says that the full data on La Jolla's CRH treatment, LJPC-501, should result in approval by the FDA because the drug met its primary endpoint. The analyst adds that he was "pleasantly surprised" by the drug's attainment of its " key secondary endpoint of CV SOFA score." Suneja says that the drug's failure to improve patients' total SOFA scores is "less relevant." He keeps a $57 price target and a Buy rating on the stock.

TODAY'S FREE FLY STORIES

QCOM

Qualcomm

$58.76

-0.03 (-0.05%)

, NXPI

NXP Semiconductors

$112.55

-0.42 (-0.37%)

07:31
06/22/18
06/22
07:31
06/22/18
07:31
Hot Stocks
Qualcomm extends cash offer for NXP Semiconductors to June 29 »

Qualcomm (QCOM) announced…

QCOM

Qualcomm

$58.76

-0.03 (-0.05%)

NXPI

NXP Semiconductors

$112.55

-0.42 (-0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 10

    Jul

  • 12

    Jul

FOXA

21st Century Fox

$48.34

0.24 (0.50%)

, RIG

Transocean

$11.94

-0.575 (-4.60%)

07:30
06/22/18
06/22
07:30
06/22/18
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

FOXA

21st Century Fox

$48.34

0.24 (0.50%)

RIG

Transocean

$11.94

-0.575 (-4.60%)

CSX

CSX

$64.06

-0.81 (-1.25%)

Z

Zillow

$61.83

-2.84 (-4.39%)

KMB

Kimberly-Clark

$100.15

-1.51 (-1.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 26

    Aug

WSC

Williams Scotsman

$12.10

-0.3 (-2.42%)

07:30
06/22/18
06/22
07:30
06/22/18
07:30
Hot Stocks
Breaking Hot Stocks news story on Williams Scotsman »

WillScot Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

SENS

Senseonics

$4.96

0.1 (2.06%)

07:29
06/22/18
06/22
07:29
06/22/18
07:29
Recommendations
Senseonics analyst commentary  »

Senseonics FDA approval…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

CAKE

Cheesecake Factory

$59.87

2.13 (3.69%)

07:28
06/22/18
06/22
07:28
06/22/18
07:28
Downgrade
Cheesecake Factory rating change  »

Cheesecake Factory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WSC

Williams Scotsman

$12.10

-0.3 (-2.42%)

07:26
06/22/18
06/22
07:26
06/22/18
07:26
Conference/Events
Williams Scotsman to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

SLNO

Soleno Therapeutics

$2.34

-0.02 (-0.85%)

07:26
06/22/18
06/22
07:26
06/22/18
07:26
Initiation
Soleno Therapeutics initiated  »

Soleno Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TTD

Trade Desk

$91.53

-1.84 (-1.97%)

07:26
06/22/18
06/22
07:26
06/22/18
07:26
Recommendations
Trade Desk analyst commentary  »

Trade Desk price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRTX

Heron Therapeutics

$40.00

9.3 (30.29%)

07:25
06/22/18
06/22
07:25
06/22/18
07:25
Recommendations
Heron Therapeutics analyst commentary  »

Heron Therapeutics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

KLAC

KLA-Tencor

$110.31

0.54 (0.49%)

07:24
06/22/18
06/22
07:24
06/22/18
07:24
Downgrade
KLA-Tencor rating change  »

KLA-Tencor downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHT

Red Hat

$165.62

-3.64 (-2.15%)

07:24
06/22/18
06/22
07:24
06/22/18
07:24
Recommendations
Red Hat analyst commentary  »

Red Hat price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

CSCO

Cisco

$43.17

-0.58 (-1.33%)

07:24
06/22/18
06/22
07:24
06/22/18
07:24
Recommendations
Cisco analyst commentary  »

Cisco selloff brings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 12

    Jul

TNDM

TNDM

, DXCM

DexCom

$99.72

-0.88 (-0.87%)

07:23
06/22/18
06/22
07:23
06/22/18
07:23
Recommendations
TNDM, DexCom analyst commentary  »

Tandem Diabetes'…

TNDM

TNDM

DXCM

DexCom

$99.72

-0.88 (-0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 25

    Jun

DRI

Darden

$107.07

13.8 (14.80%)

07:22
06/22/18
06/22
07:22
06/22/18
07:22
Recommendations
Darden analyst commentary  »

Darden price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 16

    Jul

  • 17

    Jul

VSLR

Vivint Solar

$5.00

-0.05 (-0.99%)

07:20
06/22/18
06/22
07:20
06/22/18
07:20
Upgrade
Vivint Solar rating change  »

Vivint Solar upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ES

Eversource

$55.70

-0.1 (-0.18%)

, CTWS

Connecticut Water

$66.53

0.28 (0.42%)

07:20
06/22/18
06/22
07:20
06/22/18
07:20
Upgrade
Eversource, Connecticut Water rating change  »

Eversource upgraded to…

ES

Eversource

$55.70

-0.1 (-0.18%)

CTWS

Connecticut Water

$66.53

0.28 (0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVAV

AeroVironment

$59.24

-0.55 (-0.92%)

07:20
06/22/18
06/22
07:20
06/22/18
07:20
Conference/Events
AeroVironment to host analyst and investor meeting »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

CIT

CIT Group

$50.87

-0.42 (-0.82%)

, GS

Goldman Sachs

$227.03

-0.77 (-0.34%)

07:18
06/22/18
06/22
07:18
06/22/18
07:18
Recommendations
CIT Group, Goldman Sachs analyst commentary  »

CIT a 'clear…

CIT

CIT Group

$50.87

-0.42 (-0.82%)

GS

Goldman Sachs

$227.03

-0.77 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$41.13

-0.85 (-2.03%)

07:17
06/22/18
06/22
07:17
06/22/18
07:17
Periodicals
GM to build Chevrolet Blazer in Mexico, Reuters reports »

General Motors is moving…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPLO

Diplomat Pharmacy

$27.64

0.035 (0.13%)

07:16
06/22/18
06/22
07:16
06/22/18
07:16
Recommendations
Diplomat Pharmacy analyst commentary  »

Diplomat Pharmacy price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:15
06/22/18
06/22
07:15
06/22/18
07:15
General news
Treasury Market Outlook: Treasury yields have edged up »

Treasury Market Outlook:…

AAP

Advance Auto Parts

$139.50

0.43 (0.31%)

07:14
06/22/18
06/22
07:14
06/22/18
07:14
Recommendations
Advance Auto Parts analyst commentary  »

Advance Auto Parts price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMG

Chipotle

$462.87

-2.66 (-0.57%)

07:13
06/22/18
06/22
07:13
06/22/18
07:13
Recommendations
Chipotle analyst commentary  »

Chipotle price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 26

    Jul

ENLAY

Enel

$0.00

(0.00%)

07:13
06/22/18
06/22
07:13
06/22/18
07:13
Upgrade
Enel rating change  »

Enel upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EDRVF

EDP Renovaveis

$0.00

(0.00%)

07:11
06/22/18
06/22
07:11
06/22/18
07:11
Downgrade
EDP Renovaveis rating change  »

EDP Renovaveis downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.